Omeros マネジメント

マネジメント基準チェック /24

Omerosの CEO はGreg Demopulosで、 Jun1994年に任命され、の在任期間は 30.42年です。の年間総報酬は$ 7.69Mで、 11.9%給与と88.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.5%を直接所有しており、その価値は$ 22.11M 。経営陣と取締役会の平均在任期間はそれぞれ4.9年と17.9年です。

主要情報

Greg Demopulos

最高経営責任者

US$7.7m

報酬総額

CEO給与比率	11.9%
CEO在任期間	30.4yrs
CEOの所有権	3.5%
経営陣の平均在職期間	4.9yrs
取締役会の平均在任期間	17.9yrs

経営陣の近況

Recent updates

Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Jun 05

Omeros posts preliminary results from COVID-19 patients treated with narsoplimab

May 28

CEO報酬分析

Omeros の収益と比較して、Greg Demopulos の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$185m
Jun 30 2024	n/a	n/a	-US$200m
Mar 31 2024	n/a	n/a	-US$179m
Dec 31 2023	US$8m	US$917k	-US$175m
Sep 30 2023	n/a	n/a	-US$182m
Jun 30 2023	n/a	n/a	-US$185m
Mar 31 2023	n/a	n/a	-US$182m
Dec 31 2022	US$4m	US$882k	-US$182m
Sep 30 2022	n/a	n/a	-US$183m
Jun 30 2022	n/a	n/a	-US$173m
Mar 31 2022	n/a	n/a	-US$181m
Dec 31 2021	US$7m	US$848k	-US$192m
Sep 30 2021	n/a	n/a	-US$217m
Jun 30 2021	n/a	n/a	-US$211m
Mar 31 2021	n/a	n/a	-US$194m
Dec 31 2020	US$6m	US$817k	-US$173m
Sep 30 2020	n/a	n/a	-US$130m
Jun 30 2020	n/a	n/a	-US$108m
Mar 31 2020	n/a	n/a	-US$89m
Dec 31 2019	US$5m	US$794k	-US$147m
Sep 30 2019	n/a	n/a	-US$79m
Jun 30 2019	n/a	n/a	-US$102m
Mar 31 2019	n/a	n/a	-US$121m
Dec 31 2018	US$5m	US$770k	-US$127m
Sep 30 2018	n/a	n/a	-US$120m
Jun 30 2018	n/a	n/a	-US$88m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$5m	US$748k	-US$53m

報酬と市場: Gregの総報酬 ($USD 7.69M ) は、 US市場 ($USD 3.17M ) の同規模の企業の平均を上回っています。

報酬と収益: Gregの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Greg Demopulos (65 yo)

30.4yrs

在職期間

US$7,689,843

報酬

Dr. Gregory A. Demopulos, M.D., also known as Greg, founded Omeros Corporation in June 1994 and has been its Chairman of the Board, Chief Executive Officer and President since June 1994. Dr. Demopulos serv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Gregory Demopulos	Co-Founder	30.4yrs	US$7.69m	3.5% $ 22.1m
Peter Cancelmo	VP, General Counsel & Corporate Secretary	5.4yrs	US$852.63k	0.00035% $ 2.2k
Pamela Palmer	Co-Founder	no data	データなし	データなし
David Borges	VP of Finance	less than a year	データなし	0.052% $ 327.3k
George Gaitanaris	Chief Scientific Officer & VP of Science	12.8yrs	データなし	データなし
Peter Williams	Vice President of Human Resources	4.4yrs	データなし	データなし
Catherine Melfi	Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems	12.1yrs	データなし	データなし
Nadia Dac	VP & Chief Commercial Officer	3.8yrs	データなし	データなし
Andreas Grauer	VP & Chief Medical Officer	1.1yrs	データなし	データなし

4.9yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: OMERの経営陣は経験豊富であると考えられます ( 4.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Gregory Demopulos	Co-Founder	30.4yrs	US$7.69m	3.5% $ 22.1m
Thomas Cable	Lead Independent Director	29.8yrs	US$177.60k	0.061% $ 382.6k
Leroy Hood	Independent Director	23.7yrs	US$135.10k	0.13% $ 811.6k
Arnold Hanish	Independent Director	12.2yrs	US$137.60k	0.021% $ 135.3k
Peter Demopulos	Director	29.8yrs	US$122.60k	0.64% $ 4.1m
Thomas Bumol	Independent Director	5.8yrs	US$127.60k	0.017% $ 109.1k
Rajiv Shah	Independent Director	9.4yrs	US$140.10k	0% $ 0
Diana Perkinson	Independent Director	1.5yrs	US$174.66k	0% $ 0

17.9yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: OMERの取締役会は経験豊富で経験豊富です ( 17.9年の平均在任期間)。

Omeros マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Omeros Corporation Announces Executive Changes

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Insufficient new directors

Recent updates

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns

Omeros Corporation to Report Q3, 2024 Results on Nov 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros' MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Omeros Corporation to Report Q2, 2024 Results on Aug 07, 2024

Omeros: Troubled Company Working Its Way Out Of The Morass

Omeros Corporation Announces Executive Changes

Omeros Corporation announced that it expects to receive $92.1 million in funding

Omeros Corporation to Report Q1, 2024 Results on May 15, 2024

Omeros Corporation, Annual General Meeting, Jun 06, 2024

Omeros Corporation (NasdaqGM:OMER) announces an Equity Buyback for $50 million worth of its shares.

Omeros Corporation to Report Q4, 2023 Results on Apr 01, 2024

Omeros: Still Worth A Look Despite Narsoplimab Woes

New major risk - Share price stability

New major risk - Negative shareholders equity

Omeros Corporation to Report Q3, 2023 Results on Nov 09, 2023

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Price target decreased by 17% to US$5.83

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

New minor risk - Market cap size

Omeros Corporation to Report Q2, 2023 Results on Aug 09, 2023

Is Omeros (NASDAQ:OMER) A Risky Investment?

Omeros Corporation, Annual General Meeting, Jun 23, 2023

Kurt Zumwalt Not to Stand for Re-Election as Class II Director of Omeros Corporation

Omeros Corporation to Report Q1, 2023 Results on May 09, 2023

Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Price target increased by 17% to US$7.00

No longer forecast to breakeven

Consensus revenue estimates increase by 113%

Insufficient new directors

Omeros Corporation to Report Q3, 2022 Results on Nov 09, 2022

Omeros: Taking It To The Max

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

Omeros falls 11% after reporting clinical data for COVID-19 therapy

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

Omeros: Managing An Investment After A Winning Trade

Omeros Corporation to Report Q2, 2022 Results on Aug 09, 2022

Omeros granted FDA’s Orphan Drug designation for PNH candidate

Omeros: Follow The Bouncing Ball

Price target increased to US$16.00

Omeros: On Death's Door

First quarter 2022 earnings released: US$0.63 loss per share (vs US$0.57 loss in 1Q 2021)

Omeros Corporation to Report Q1, 2022 Results on May 10, 2022

Consensus revenue estimates fall by 35%

No longer forecast to breakeven

Omeros Corporation, Annual General Meeting, Jun 17, 2022

Omeros: The Weight Of The Wait, A Conundrum

Insufficient new directors

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Insufficient new directors

Omeros Corporation to Report Q4, 2021 Results on Mar 01, 2022

Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA

Price target decreased to US$15.00

Forecast to breakeven in 2024

Rayner Surgical Inc. completed the acquisition of OMIDRIA Franchise from Omeros Corporation (NasdaqGM:OMER).

Omeros: A New Year Beckons

Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Consensus revenue estimates increase to US$129.6m

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.66 loss in 3Q 2020)

Price target decreased to US$22.50

Omeros: What's Left

Price target decreased to US$25.29

Omeros: The Prize Is Nigh (Again)

Independent Director exercised options to buy US$156k worth of stock.

マネジメント基準チェック /24